Dupixent Lawsuit

---

If you or someone you love developed cutaneous T-cell lymphoma after taking Dupixent, you may have legal options.

Dupixent is a prescription medication used to treat eczema, asthma, and several other inflammatory conditions. For many patients, the medication provides meaningful relief from symptoms that can be difficult to manage.

However, medical researchers have raised concerns about a possible association between Dupixent and cutaneous T-cell lymphoma (CTCL), a rare form of cancer that affects certain white blood cells and commonly appears in the skin.

Some patients who received Dupixent for eczema were subsequently diagnosed with CTCL, including mycosis fungoides and Sézary syndrome.

The relationship between Dupixent and these cancers is still being investigated. Researchers are examining whether the medication may contribute to the development of lymphoma, worsen an existing cancer, or reveal a disease that was initially mistaken for eczema.

Lawsuits have also been filed against the companies responsible for Dupixent, alleging that patients and healthcare providers were not adequately warned about these potential risks.

If you have been diagnosed with T-cell lymphoma after receiving Dupixent, you deserve answers.

Call toll-free 1-866-777-2557 or complete our online contact form. A lawyer will respond within 24 hours to answer your questions and help you understand your legal options.

Dupixent (dupilumab) is an injectable prescription medication developed by Regeneron Pharmaceuticals and Sanofi.

The U.S. Food and Drug Administration first approved Dupixent in 2017 for the treatment of certain patients with moderate-to-severe atopic dermatitis, commonly known as eczema.

Since then, the FDA has approved the medication for additional conditions, including certain forms of asthma, chronic sinusitis with nasal polyps, eosinophilic esophagitis, and other inflammatory diseases.

Dupixent is a biologic medication that works by blocking signaling associated with two immune-system proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13).

These proteins play important roles in inflammation.

By interrupting their signaling, Dupixent can reduce inflammation and relieve symptoms such as itching, skin irritation, and breathing difficulties.

However, researchers are investigating whether modifying these immune pathways may have unintended effects in certain patients, particularly those with an existing or previously undiagnosed T-cell lymphoma.

Cutaneous T-cell lymphoma is a rare form of non-Hodgkin lymphoma involving T lymphocytes, a type of white blood cell.

In many patients, the cancer initially affects the skin, causing symptoms that can resemble eczema or other inflammatory skin conditions.

This similarity creates an important medical challenge.

Some patients diagnosed with eczema and prescribed Dupixent may already have had an undiagnosed form of CTCL.

Researchers have identified several possible explanations for cases of CTCL diagnosed during Dupixent treatment:

• Previously undiagnosed lymphoma: A patient may have had CTCL that was originally mistaken for eczema.
• Unmasking an existing disease: Changes during treatment may make a previously unrecognized lymphoma more apparent.
• Acceleration of existing lymphoma: Researchers are examining whether Dupixent could worsen or accelerate CTCL in certain patients.
• Development of new lymphoma: Some studies have raised concerns about a possible increased risk of CTCL following treatment, although a causal relationship has not been established.

These possibilities are not mutually exclusive, and the explanation may differ from patient to patient.

The important distinction is that a CTCL diagnosis following Dupixent treatment does not, by itself, prove that the medication caused the cancer.

Nevertheless, the reported association has prompted scientific research, FDA safety monitoring, and pharmaceutical product liability lawsuits.

Medical researchers have published numerous reports describing patients diagnosed with CTCL during or after Dupixent treatment.

In March 2026, researchers published a systematic review and expert consensus examining 51 studies involving 547 patients with reported CTCL occurring during Dupixent therapy.

The review focused particularly on mycosis fungoides and Sézary syndrome.

Researchers concluded that Dupixent may unmask or worsen previously existing CTCL in some patients and emphasized the importance of distinguishing lymphoma from eczema before and during treatment.

However, the findings do not establish that Dupixent caused all, or any particular, cases of lymphoma.

One reason the issue is difficult to study is that CTCL can resemble eczema for years before an accurate diagnosis is made.

Researchers continue to investigate the potential relationship between Dupixent, immune-system changes, and the progression or recognition of T-cell lymphoma.

The FDA has identified cutaneous T-cell lymphoma as a potential safety concern associated with Dupixent.

In its report covering the fourth quarter of 2024, the agency listed Dupixent and CTCL among potential signals of serious risks identified through its adverse-event monitoring system.

The FDA stated that it was evaluating whether regulatory action was necessary.

An FDA safety signal does not establish that a medication caused the reported medical condition. It means that the available information warrants further investigation.

As of the April 2026 U.S. prescribing information, CTCL was not listed as an established adverse reaction in the medication's warnings and precautions.

Other serious risks and precautions are identified in Dupixent's prescribing information, including certain allergic reactions, eye problems, and eosinophilic conditions.

Patients should discuss concerns about Dupixent with their prescribing healthcare professional rather than independently stopping or changing their medication.

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma.

Despite its name, it is not a fungal infection.

The disease often begins with persistent patches of irritated, discolored, or scaly skin that can be mistaken for eczema or psoriasis.

Some patients experience itching, thickened skin, raised plaques, or tumor-like lesions.

Because early mycosis fungoides can resemble ordinary dermatitis, patients may undergo years of treatment before receiving an accurate diagnosis.

Sézary syndrome is a less common form of CTCL that affects the skin and blood.

Patients may develop widespread redness, severe itching, peeling skin, enlarged lymph nodes, and other symptoms.

It is generally a more aggressive condition than early-stage mycosis fungoides and requires specialized medical care.

Both conditions are important to the emerging Dupixent litigation.

The symptoms of CTCL can be difficult to distinguish from eczema, particularly during the early stages.

Possible warning signs include:

• Persistent or worsening skin rashes
• Severe or increasing itching
• Red, discolored, or scaly skin patches
• Thickened or raised skin lesions
• New lumps or nodules on the skin
• Widespread skin redness or peeling
• Enlarged lymph nodes
• Hair loss or unusual changes in skin texture

These symptoms do not necessarily mean someone has cancer. Many are also caused by common dermatological conditions.

However, patients experiencing persistent, unusual, or worsening symptoms while receiving Dupixent should discuss them with their physician.

A dermatologist may recommend additional evaluation, including a skin biopsy. More than one biopsy may sometimes be needed to establish a diagnosis.

Early evaluation is particularly important when a skin condition does not respond as expected to treatment.

Some patients have reported worsening skin symptoms during Dupixent treatment before being diagnosed with CTCL.

For example, a person may have received Dupixent for eczema and initially experienced improvement, only to develop new lesions, worsening itching, or other unusual symptoms later.

Others may have experienced little improvement from the beginning.

These circumstances do not establish that Dupixent caused lymphoma, but they may warrant further medical investigation.

If you received a CTCL diagnosis after taking Dupixent, the history of your symptoms, treatments, and previous biopsies may be relevant to understanding what happened.

Product liability lawsuits have been filed against Regeneron Pharmaceuticals, Sanofi-Aventis, and related corporate entities.

The lawsuits generally allege that Dupixent caused or aggravated T-cell lymphoma and that the companies failed to provide adequate warnings about the alleged risks.

Some claims involve patients who developed CTCL following treatment. Others involve allegations that Dupixent accelerated an existing lymphoma.

The companies' legal responsibility and the scientific questions underlying these claims remain unresolved.

On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation ordered related federal Dupixent lawsuits transferred to the District of New Jersey.

The coordinated proceedings are known as:

In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180.

The litigation is assigned to U.S. District Judge Zahid N. Quraishi.

Multidistrict litigation allows related federal lawsuits to share coordinated pretrial proceedings, including document discovery, depositions, and consideration of common scientific and legal issues.

It is not the same thing as a class action lawsuit.

Individual plaintiffs generally retain their own claims, and the formation of an MDL does not establish that Dupixent caused any patient's cancer or that the manufacturers are liable.

You may want to speak with an attorney if:

• You received Dupixent (dupilumab) injections.
• You were later diagnosed with cutaneous T-cell lymphoma.
• Your diagnosis included mycosis fungoides or Sézary syndrome.
• You experienced a worsening or progression of previously diagnosed CTCL during treatment.
• A spouse or family member died after a diagnosis of T-cell lymphoma following Dupixent use.

The timing of medication use, medical history, diagnosis, and other circumstances are important.

Taking Dupixent alone does not establish eligibility for a lawsuit, and not every lymphoma diagnosis is part of the current litigation.

An attorney can review the facts and explain whether further investigation may be appropriate.

Depending on the evidence and applicable law, individuals pursuing a viable Dupixent product liability claim may seek compensation for:

• Medical bills and cancer treatment expenses
• Lost income and diminished earning capacity
• Pain and suffering
• Future medical care and related expenses
• Other financial and personal losses associated with the disease

Families who have lost a loved one may also have options under applicable wrongful death laws.

The availability and amount of compensation depend on the facts of the case. No settlement or recovery is guaranteed.

If you have been diagnosed with CTCL after using Dupixent, several types of records may be helpful.

Medication records: Prescription histories, specialty pharmacy records, injection dates, and information about when treatment began and ended.

Medical history: Dermatology appointments, diagnoses, biopsy results, pathology reports, and oncology records.

Symptom history: When skin problems first appeared, whether they changed during treatment, and when the lymphoma was diagnosed.

Personal records: Photographs of skin changes, appointment summaries, or notes about your symptoms.

Do not worry if you do not have all of these records available.

An attorney can explain what information may be useful and how additional records can be obtained.

The relationship between Dupixent and certain T-cell lymphomas remains under scientific investigation.

Studies have reported CTCL diagnoses during or after Dupixent treatment, but a causal relationship has not been conclusively established.

Researchers are examining whether the medication may unmask, worsen, or potentially contribute to lymphoma in some patients.

Dupixent has not been recalled because of the

 reported CTCL concern. The FDA continues to monitor potential risks, and the medication remains approved for several medical conditions.

No. The centralized federal litigation primarily involves cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome.

The potential treatment of claims involving other T-cell lymphomas remains a developing issue. Other cancers are not automatically included.

That history may be particularly important.

Early CTCL can resemble eczema, and some patients receive treatment for inflammatory skin conditions before lymphoma is identified.

Medical records and earlier biopsy findings may help clarify the sequence of events.

Do not stop or change a prescribed medication based solely on information about lawsuits.

Discuss your concerns and any unusual or worsening symptoms with your treating healthcare professional. Your physician can evaluate your individual medical situation and determine whether treatment changes or additional testing are appropriate.

Surviving family members may have legal options depending on the circumstances and applicable law.

An attorney can review the diagnosis, medication history, and potential wrongful death claims.

Legal deadlines vary by state and the type of claim.

Because determining when a claim accrued can involve complicated medical and legal questions, it is important to seek advice promptly.

Patients take prescription medications because they trust that the benefits and risks have been carefully studied and communicated.

When a serious diagnosis follows treatment, patients and families understandably want to know whether the medication played a role.

If you or someone you love developed cutaneous T-cell lymphoma after receiving Dupixent, you may have legal options worth investigating.

You do not need to understand the science, identify every potentially responsible company, or have all your medical records before speaking with an attorney.

Call toll-free 1-866-777-2557 or complete our online contact form.

A lawyer will respond within 24 hours to answer your questions.

You deserve answers, and you shouldn't have to search for them alone.